Recordati resists EUR51.29: why the offer is a EUR1.3 billion test for GBL

GBL intends to invest up to about EUR1.3 billion in Recordati, an Italian pharmaceutical group focused on medicines and rare diseases. The transaction should embody its new strategy: fewer dispersed financial holdings and more controlled or jointly controlled private companies. Several minority investors, however, are challenging the EUR51.29 price. Their opposition turns the offer into an execution test for the holding company.

What is Recordati?

Recordati develops and sells medicines through two main engines: specialty treatments for broad markets and rare-disease medicines serving small patient populations with significant medical needs.

This profile interests GBL because it combines recurring pharmaceutical revenue, international growth and acquisition potential. The holding company is not seeking a small financial stake. Alongside CVC, it wants to jointly control Recordati, take it private and influence strategy over a long period.

This article therefore continues our analysis of GBL's more than EUR5 billion of disposals and its move from influence to control. Recordati is where that doctrine meets the reality of price and minority shareholders.

How the offer is structured

GBL and CVC are offering EUR51.29 per share and aim to delist Recordati. The offer's maximum value is EUR10.726 billion, while GBL expects to commit up to about EUR1.3 billion, with the rest of the structure primarily supported alongside CVC.

Rossini, the existing CVC-controlled vehicle, has committed to tender 97,912,463 shares, or 46.82% of capital. The offer must reach at least 66.67% of capital. It therefore needed close to another 19.85 percentage points before additional tenders.

At 16 September, the market notice recorded 98,281,125 tendered shares in total. Excluding Rossini's block, additional tenders represented only about 368,662 shares, or 0.18% of capital. This is a moving snapshot: tenders may accelerate before the 15 October closing date.

Why some shareholders are resisting

The Financial Times reports that six minority shareholders oppose the price. Recordati's four independent directors also reportedly considered it financially inadequate. Those are their assessments. They do not by themselves prove that the price is too low.

Their implicit argument is straightforward: accepting EUR51.29 provides immediate liquidity but gives up any future value from medicine growth, the rare-disease portfolio and acquisitions. Refusing creates the opposite risk: remaining a minority investor in a less liquid company if control changes without a complete delisting.

Why GBL shareholders are directly concerned

A EUR1.3 billion commitment is about 10% of GBL's net asset value published at 31 March. It is large enough to change the portfolio and to test the pricing discipline promised by the holding company.

Success will not be measured only by reaching the threshold. Paying more to secure more shares could facilitate a delisting but reduce expected future returns. Maintaining the price protects financial discipline but may leave a listed structure with minority shareholders and more complex governance.

GBL recently had substantial liquidity and an LTV of 0.0% under its own definition, meaning net cash offset the debt included in that calculation. The question is not immediate financing capacity. It is whether the price paid and governance obtained will produce an adequate long-term return.

Three outcomes, three different readings

First, the threshold is reached at the current price and the delisting succeeds. GBL can then implement joint control in a private setting.

Second, the threshold is reached but a full delisting fails. GBL and CVC control a company that retains minority investors, with additional governance and market constraints.

Third, tenders remain insufficient or other conditions are not met. GBL keeps its liquidity but its first major private redeployment is delayed.

The next decisive number is therefore the acceptance rate as 15 October approaches, followed by any change in price or conditions. For GBL shareholders, Recordati is not merely a pharmaceutical acquisition: it is the first public examination of the new way the holding company promises to allocate several billion euros.

This content is general financial information. It is not investment advice, a solicitation or a personalised recommendation concerning the offer.